Detecting tumor progression in glioma: current standards and new techniques

Jean Guy Belliveau, Glenn Bauman, David R. Macdonald

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Introduction: The post-treatment monitoring of glioma patients remains an area of active research and development. Conventional imaging with MRI is a highly sensitive modality for detecting and monitoring primary and secondary brain tumors and includes multi-parametric sequences to better characterize the disease. Standardized schemes for measuring response to treatment are in wide clinical use; however, the introduction of new therapeutics have introduced new patterns of response that can confound interpretation of conventional MRI and can cause uncertainty in the proper management following therapy. Areas covered: A summary of current and evolving techniques for assessing glioma response in this era of new therapies that address these challenges are presented in this review. While this review focuses more on clinical and early clinical methodologies for MRI and nuclear medicine techniques some promising pre-clinical techniques are also presented. Expert commentary: While successful single institution results have been widely reported in the literature, any new methodologies must be undertaken in multi-center settings. Additionally, the need for standardization of protocols in quantitative measured are an important area that must be addressed for new and promising techniques to be implemented to a wide array of patients.

Original languageEnglish (US)
Pages (from-to)1177-1188
Number of pages12
JournalExpert Review of Anticancer Therapy
Volume16
Issue number11
DOIs
StatePublished - Nov 1 2016

Fingerprint

Glioma
Neoplasms
Therapeutics
Nuclear Medicine
Physiologic Monitoring
Brain Neoplasms
Uncertainty
Research

Keywords

  • Glioma
  • MRI
  • concurrent radiochemotherapy
  • glioblastoma
  • pseudoprogression
  • pseudoresponse

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Detecting tumor progression in glioma : current standards and new techniques. / Belliveau, Jean Guy; Bauman, Glenn; Macdonald, David R.

In: Expert Review of Anticancer Therapy, Vol. 16, No. 11, 01.11.2016, p. 1177-1188.

Research output: Contribution to journalReview article

Belliveau, Jean Guy ; Bauman, Glenn ; Macdonald, David R. / Detecting tumor progression in glioma : current standards and new techniques. In: Expert Review of Anticancer Therapy. 2016 ; Vol. 16, No. 11. pp. 1177-1188.
@article{cec2535f90e64d25960c4059e3888024,
title = "Detecting tumor progression in glioma: current standards and new techniques",
abstract = "Introduction: The post-treatment monitoring of glioma patients remains an area of active research and development. Conventional imaging with MRI is a highly sensitive modality for detecting and monitoring primary and secondary brain tumors and includes multi-parametric sequences to better characterize the disease. Standardized schemes for measuring response to treatment are in wide clinical use; however, the introduction of new therapeutics have introduced new patterns of response that can confound interpretation of conventional MRI and can cause uncertainty in the proper management following therapy. Areas covered: A summary of current and evolving techniques for assessing glioma response in this era of new therapies that address these challenges are presented in this review. While this review focuses more on clinical and early clinical methodologies for MRI and nuclear medicine techniques some promising pre-clinical techniques are also presented. Expert commentary: While successful single institution results have been widely reported in the literature, any new methodologies must be undertaken in multi-center settings. Additionally, the need for standardization of protocols in quantitative measured are an important area that must be addressed for new and promising techniques to be implemented to a wide array of patients.",
keywords = "Glioma, MRI, concurrent radiochemotherapy, glioblastoma, pseudoprogression, pseudoresponse",
author = "Belliveau, {Jean Guy} and Glenn Bauman and Macdonald, {David R.}",
year = "2016",
month = "11",
day = "1",
doi = "10.1080/14737140.2016.1240621",
language = "English (US)",
volume = "16",
pages = "1177--1188",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "11",

}

TY - JOUR

T1 - Detecting tumor progression in glioma

T2 - current standards and new techniques

AU - Belliveau, Jean Guy

AU - Bauman, Glenn

AU - Macdonald, David R.

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Introduction: The post-treatment monitoring of glioma patients remains an area of active research and development. Conventional imaging with MRI is a highly sensitive modality for detecting and monitoring primary and secondary brain tumors and includes multi-parametric sequences to better characterize the disease. Standardized schemes for measuring response to treatment are in wide clinical use; however, the introduction of new therapeutics have introduced new patterns of response that can confound interpretation of conventional MRI and can cause uncertainty in the proper management following therapy. Areas covered: A summary of current and evolving techniques for assessing glioma response in this era of new therapies that address these challenges are presented in this review. While this review focuses more on clinical and early clinical methodologies for MRI and nuclear medicine techniques some promising pre-clinical techniques are also presented. Expert commentary: While successful single institution results have been widely reported in the literature, any new methodologies must be undertaken in multi-center settings. Additionally, the need for standardization of protocols in quantitative measured are an important area that must be addressed for new and promising techniques to be implemented to a wide array of patients.

AB - Introduction: The post-treatment monitoring of glioma patients remains an area of active research and development. Conventional imaging with MRI is a highly sensitive modality for detecting and monitoring primary and secondary brain tumors and includes multi-parametric sequences to better characterize the disease. Standardized schemes for measuring response to treatment are in wide clinical use; however, the introduction of new therapeutics have introduced new patterns of response that can confound interpretation of conventional MRI and can cause uncertainty in the proper management following therapy. Areas covered: A summary of current and evolving techniques for assessing glioma response in this era of new therapies that address these challenges are presented in this review. While this review focuses more on clinical and early clinical methodologies for MRI and nuclear medicine techniques some promising pre-clinical techniques are also presented. Expert commentary: While successful single institution results have been widely reported in the literature, any new methodologies must be undertaken in multi-center settings. Additionally, the need for standardization of protocols in quantitative measured are an important area that must be addressed for new and promising techniques to be implemented to a wide array of patients.

KW - Glioma

KW - MRI

KW - concurrent radiochemotherapy

KW - glioblastoma

KW - pseudoprogression

KW - pseudoresponse

UR - http://www.scopus.com/inward/record.url?scp=84991579784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991579784&partnerID=8YFLogxK

U2 - 10.1080/14737140.2016.1240621

DO - 10.1080/14737140.2016.1240621

M3 - Review article

AN - SCOPUS:84991579784

VL - 16

SP - 1177

EP - 1188

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 11

ER -